Eight patients with active ulcerative colitis (UC). refractory to usual com
bination medical therapy, were treated with a single i.v. dose of chimeric
monoclonal antibody to recombinant human tumor necrosis factor a; many of t
hese patients were scheduled for surgical colectomy because of their active
disease. All patients responded extremely well to a single 5 mg/kg infusio
n of infliximab, with marked improvement after the infusion clinically, col
onoscopically, and histologically on colonic biopsy. There were no signific
ant complications or side effects; mean duration of remission has not been
determined because none of the patients have relapsed. Infliximab appears t
o be a potent agent for inducing remission in refractory patients with ulce
rative colitis. (C) 2001 by Am. Coll. of Gastroenterology.